Blood or marrow transplantation is the standard of care for many hematologic malignancies and selected nonmalignant diseases. Whether transplantation succeeds or fails depends, in part, on the ability of the patient to tolerate the preparative treatment. This chapter will focus on the major toxicities of myeloabla-tive preparative regimens. Reduced-intensity regimens are usually described as being nonmyeloablative. Some of these regimens are, in fact, are quite toxic. Although this is a generalization, it is safe to say that reduced-intensity regimens are associated with fewer early treatment-related deaths. Where these regimens are most appropriately used remains the subject of intense investigation. A more detailed discussion of this approach can be found elsewhere in this text.

0 0

Post a comment